OnKure Therapeutics, Inc.
OKUR · XNASCIK 1637715fmd_0CM33R04QPFGQKX060M612S48TManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | – |
| Net interest income | – | – | – | 2 | 2 | 3 |
| Research and development | 16 | 28 | 38 | 32 | 44 | 48 |
| Total operating expenses | 20 | 40 | 54 | 37 | 54 | 63 |
| Operating income | (20) | (40) | (54) | (37) | (54) | (63) |
| Other non-operating income (expense) | – | 0 | 2 | 6 | – | – |
| Income before taxes | (19) | (40) | (52) | (77) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (19) | (40) | (52) | (77) | – | – |
| Net income | (19) | (40) | (52) | (35) | (53) | (60) |